Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Evaluation of Cognitive Education Activities in Breast Cancer Patients Receiving Chemotherapy

29 de abril de 2026 atualizado por: Gizem Erdoğan, Saglik Bilimleri Universitesi

Evaluation of Cognitive Education Activities Provided to Breast Cancer Patients Receiving Chemotherapy

Breast cancer is one of the most common cancer types worldwide and accounts for approximately 31% of all cancers in women. The global incidence of breast cancer is increasing, making it a significant public health problem. Advances in breast cancer management, including surgery, chemotherapy, radiotherapy, and hormone therapy, have contributed to reduced mortality rates. However, despite these positive developments, chemotherapy-related cognitive impairment, commonly referred to as "chemobrain," may occur.

Chemotherapy-induced cognitive impairment may manifest as deficits in memory, learning, attention, motor functions, executive functions, visual-spatial abilities, and information processing speed. These impairments negatively affect patients' quality of life and daily functioning.

In this study, cognitive education activities were designed and implemented to address these impairments. These activities aimed to support attention, memory, and executive functions and to minimize cognitive deficits. The purpose of this study was to examine the effects of cognitive activities applied to breast cancer patients receiving chemotherapy on cognitive functions, depression levels, and odor recognition abilities.

The study sought to answer the following research questions:

  1. What is the effect of cognitive education activities on odor recognition ability in breast cancer patients receiving chemotherapy?
  2. What is the effect of cognitive education activities on cognitive functions in breast cancer patients receiving chemotherapy?
  3. What is the effect of cognitive education activities on depression levels in these patients?

Visão geral do estudo

Descrição detalhada

This randomized controlled trial was conducted between March 2025 and February 2026 at the oncology outpatient clinic and chemotherapy unit of Gulhane Training and Research Hospital. The study aimed to evaluate the effects of cognitive education activities on cognitive function, depression levels, and odor recognition ability in breast cancer patients receiving chemotherapy. A total of 120 patients who met the inclusion criteria were enrolled in the study. Eligible participants were between 18 and 65 years of age, literate, diagnosed with breast cancer, had received at least one cycle of chemotherapy, were continuing treatment, and had no diagnosed neurological or cognitive disorder before or during chemotherapy. In addition, participants had a Standardized Mini-Mental Test (SMMT) score of 24 or below. Participants were randomly assigned to intervention (n=60) and control (n=60) groups using a computer-generated randomization method. During the study, 12 participants withdrew for various reasons, and the study was completed with 108 participants (54 in each group). The study was designed as a single-blind, pre-test/post-test randomized controlled trial. The intervention group received structured cognitive education through printed booklets, face-to-face sessions, and weekly telephone counseling. The cognitive activity program was designed to stimulate attention, memory, executive functions, and language skills. Four cognitive activity booklets with progressively increasing difficulty levels were developed. Since chemotherapy sessions were scheduled every three weeks according to the hospital protocol, each booklet was structured to be completed over a three-week period. Face-to-face sessions were conducted every three weeks, resulting in a total of five sessions over a 12-week period. During these sessions, participants completed structured cognitive activities included in the activity booklets, such as sudoku, puzzles, sentence completion, pattern recognition, word derivation, coloring, and reading comprehension exercises, all of which were designed to support cognitive functions. Weekly telephone follow-ups were conducted to enhance adherence to the intervention. To assess olfactory function, odor identification tasks were performed using non-transparent containers. Familiar scents such as lavender, coffee, lemon, orange, onion, rose water, and cinnamon were used. The control group received routine care without any cognitive intervention during the study period. After completion of the study, the control group was also provided with cognitive activity training and the educational materials used in the intervention. Data were collected using a sociodemographic data form, an odor identification test, the Standardized Mini-Mental Test (SMMT), the Functional Assessment of Cancer Therapy - Cognitive Function (FACT-Cog) scale (Version 3), and the Beck Depression Inventory (BDI). Measurements were conducted at baseline and at 12 weeks following the initial assessment.

Tipo de estudo

Intervencional

Inscrição (Real)

108

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

    • Etlik
      • Ankara, Etlik, Turquia (Türkiye), 06010
        • Health Sciences University Gulhane Training and Research Hospital

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

  • Adulto
  • Adulto mais velho

Aceita Voluntários Saudáveis

Não

Descrição

Inclusion Criteria:

Participants were eligible if they met all of the following criteria:

  • Aged between 18 and 65 years
  • Literate
  • Diagnosed with breast cancer
  • Had received at least one cycle of chemotherapy and were currently undergoing chemotherapy
  • Had a Standardized Mini-Mental Test (SMMT) score of 24 or below
  • Had no diagnosed cognitive, neurological, or psychiatric disorder prior to chemotherapy

Exclusion Criteria:

Participants were excluded if they met any of the following criteria:

  • Age over 65 years
  • SMMT score above 24
  • Presence of brain metastases
  • Presence of neurological or medical conditions affecting cognitive function
  • Diagnosed psychiatric disorder
  • Current use of central nervous system depressants, stimulants, or psychiatric medications
  • History of alcohol or substance abuse

Withdrawal Criteria:

Participants were withdrawn from the study if any of the following occurred:

  • Discontinuation of chemotherapy treatment
  • Inability to attend follow-up visits regularly
  • Failure to complete the cognitive activity booklet tasks
  • Loss of contact or inability to reach the participant
  • Voluntary withdrawal from the study
  • Death during the study period

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Cuidados de suporte
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Solteiro

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Sem intervenção: Control Group (Routine Care)
Participants in the control group received routine chemotherapy follow-up and standard care without any additional cognitive intervention during the study period.
Experimental: Intervention Group (Cognitive Education)
Participants in the intervention group received structured cognitive function training activities in addition to routine care. The intervention was delivered using printed activity booklets designed to support cognitive function.
Participants received structured cognitive training through printed activity booklets designed to support attention, memory, executive functions, and language skills. The booklets included activities such as puzzles, word derivation, sentence completion, pattern recognition, coloring, reading comprehension, and sudoku. Four booklets with progressively increasing difficulty levels were provided over a 12-week period. Each booklet was designed to be completed over three weeks. The intervention was supported by face-to-face sessions and weekly telephone follow-ups to enhance adherence.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Change in Cognitive Function (Standardized Mini-Mental Test)
Prazo: From baseline to the end of the 12-week intervention period
Cognitive function was assessed using the Standardized Mini-Mental State Examination (SMMSE/SMMT). The scale evaluates global cognitive status across domains including orientation, registration, attention and calculation, recall, and language. Scores range from 0 to 30, where 30 represents maximum cognitive function and scores below 24 may indicate cognitive impairment. Higher scores indicate better cognitive performance.
From baseline to the end of the 12-week intervention period

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Change in Subjective Cognitive Function (Functional Assessment of Cancer Therapy - Cognitive Function)
Prazo: From baseline to the end of the 12-week intervention period
Subjective cognitive function was assessed using the Functional Assessment of Cancer Therapy - Cognitive Function (FACT-Cog) Version 3. This self-report scale consists of 37 items categorised into four subscales: Perceived Cognitive Impairment, Comments from Others, Perceived Cognitive Abilities, and Impact of Cognitive Impairment on Quality of Life. Each item is rated on a 5-point Likert scale (0=Not at all to 4=Very much), with higher total scores indicating better perceived cognitive health and fewer cognitive complaints.
From baseline to the end of the 12-week intervention period
Change in Depression Level (Beck Depression Inventory)
Prazo: From baseline to the end of the 12-week intervention period
Depression levels were assessed using the Beck Depression Inventory (BDI), a 21-item self-report scale evaluating the severity of depressive symptoms. Total scores range from 0 to 63, with higher scores indicating more severe depressive symptoms.
From baseline to the end of the 12-week intervention period
Odor Recognition Ability
Prazo: From baseline to the end of the 12-week intervention period
Odor recognition ability was assessed using a structured odor identification test consisting of 8 common odors presented in opaque (non-transparent) containers. Participants were asked to smell each container and indicate whether they could correctly recognize the odor. The assessment was based on whether each odor was correctly identified or not, rather than a numerical scoring system. The odors included familiar scents such as coffee, lavender, lemon, orange, onion, rose water, cinnamon, and mint.
From baseline to the end of the 12-week intervention period

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Investigador principal: Gizem Erdoğan, Hemşire, Health Sciences University Gulhane Training and Research Hospital
  • Diretor de estudo: Betülay Kılıç, Doçent Doktor, Health Sciences University Gülhane Faculty of Nursing

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

3 de março de 2025

Conclusão Primária (Real)

24 de fevereiro de 2026

Conclusão do estudo (Real)

2 de março de 2026

Datas de inscrição no estudo

Enviado pela primeira vez

9 de abril de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

29 de abril de 2026

Primeira postagem (Real)

6 de maio de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

6 de maio de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

29 de abril de 2026

Última verificação

1 de abril de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Descrição do plano IPD

Individual participant data will not be shared publicly. The data were collected as part of a single-center randomized controlled trial conducted for academic thesis purposes and will not be made available for external use.

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever